The Sterility Signal: Predicting Warning Letter Risk Before It Happens

Live on Tuesday, August 25 at 8 AM PST

A sterility citation on a 483 carries more escalation risk than almost any other finding, and most facilities do not see that risk coming until enforcement is already underway.

This webinar will draw on enforcement data from Redica's global inspection database covering FDA 483s, Warning Letters, and EMA/MHRA reports since 2022. We'll break down the sterility compliance failures most likely to trigger escalation and introduce a predictive model that estimates Warning Letter risk at the moment a 483 is issued. We'll also examine how EU GMP Annex 1 has raised the bar for Contamination Control Strategies, and what inspectors are actively citing now.

In this webinar, you will learn:

• Which sterility and contamination findings disproportionately drive Warning Letter escalation
• The top sterility compliance challenge areas appearing across FDA 483s today
• How a data-driven risk model identifies the factors that most elevate enforcement risk after a 483 is issued
• How EU GMP Annex 1 is reshaping MHRA inspection focus and CCS expectations

Designed for Quality, Compliance, and Manufacturing leaders overseeing sterile and aseptic operations, this session will show how enforcement data can help you anticipate risk, prioritize remediation, and strengthen your sterility assurance program before your next inspection.